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Background: Patients with squamous cell carcinoma in the head and neck region (HNSCC) offer a diagnostic
challenge due to difficulties to detect small tumours and metastases. Imaging methods available are not sufficient,
and radio-immunodiagnostics could increase specificity and sensitivity of diagnostics. The objective of this study
was to evaluate, for the first time, the in vivo properties of the radiolabelled CD44v6-targeting fragment AbD15179
and to assess its utility as a targeting agent for radio-immunodiagnostics of CD44v6-expressing tumours.
Methods: The fully human CD44v6-targeting Fab fragment AbD15179 was labelled with 111In or 125I, as models for
radionuclides suitable for imaging with SPECT or PET. Species specificity, antigen specificity and internalization
properties were first assessed in vitro. In vivo specificity and biodistribution were then evaluated in tumour-bearing
mice using a dual-tumour and dual-isotope setup.
Results: Both species-specific and antigen-specific binding of the conjugates were demonstrated in vitro, with no
detectable internalization. The in vivo studies demonstrated specific tumour binding and favourable tumour targeting
properties for both conjugates, albeit with higher tumour uptake, slower tumour dissociation, higher tumour-to-blood
ratio and higher CD44v6 sensitivity for the 111In-labelled fragment. In contrast, the 125I-Fab demonstrated more
favourable tumour-to-organ ratios for liver, spleen and kidneys.
Conclusions: We conclude that AbD15179 efficiently targets CD44v6-expressing squamous cell carcinoma xenografts,
and particularly, the 111In-Fab displayed high and specific tumour uptake. CD44v6 emerges as a suitable target for
radio-immunodiagnostics, and a fully human antibody fragment such as AbD15179 can enable further clinical imaging
studies.
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Squamous cell carcinoma of the head and neck region
(HNSCC) makes up approximately 5% of all solid can-
cers in Europe and North America. In 2008, the world-
wide incidence of oral cavity cancer was estimated to
263,900 cases [1]. Squamous cell carcinoma (SCC) is the* Correspondence: anna-karin.haylock@surgsci.uu.se
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in any medium, provided the original work is pmost common histopathological type in head and neck
cancer and occurs in the oral cavity, pharynx, sino-nasal
cavity and larynx. The oral cavity is presently the pre-
dominant site, although pharyngeal cancer is becoming
more common due to infections with human papil-
loma viruses [2,3]. Still, tobacco use is the outstanding
risk factor and particularly in combination with alco-
hol [4,5].
Already at diagnosis, 60% of HNSCC patients have
metastatic disease [6], most commonly locoregional metas-
tasis in the lymph nodes in the neck. Treatment of HNSCC
generally involves several modalities in combination suchan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and targeted therapy using antibodies. Despite the fact that
treatments have improved, there is still a high risk of dis-
ease recurrence. In the last 30 years, survival rates have
only improved slightly, with the exception of HPV-induced
carcinomas [7].
A cornerstone in the work-up of patients with HNSCC
is accurate imaging of the primary tumour and metasta-
ses, since tumour stage strongly correlates to prognosis
and hence the chosen treatment. The imaging methods
available in clinical use today are computed tomography
(CT), magnetic resonance imaging (MRI), ultrasound
and fludeoxyglucose-positron emission tomography/CT
(FDG-PET/CT). FDG-PET/CT is a valuable method when
searching for metastases and primary tumours. However,
its specificity is limited due to increased FDG uptake in
benign lymphadenitis, other inflammatory processes or
after treatment. Also, small clusters of cancer cells can es-
cape diagnosis due to the limiting size factor of the PET/
CT technique [8]. More specific imaging techniques for
HNSCC could both improve the delineation of the pri-
mary tumour for more precise surgical removal and more
accurately find lymph node metastases.
One promising method that may improve the manage-
ment of patients with head and neck malignancies is
radio-immunodiagnostics, which combines the high
sensitivity and resolution of a PET or single-photon
emission tomography (SPECT) camera with the tumour
specificity of an antibody or antibody fragment. Such radi-
olabelled monoclonal antibodies (mAbs) can be utilized
not only in the detection of metastatic lesions and primary
tumours but also in applications that include monitoring
of tumour response to therapy, dosimetric calculations,
and therapy [9]. Although intact mAbs are still most
commonly used, they are not considered optimal for
radio-immunodiagnostics. Their relatively large size (ap-
proximately 150 kDa) tends to cause unfavourable im-
aging kinetics due to slow plasma clearance, poor tumour
penetration and higher risk of eliciting a host antibody
response [10-12]. One solution to these obstacles has
been to reduce the size of intact antibodies to smaller
fragments, achieved either through enzymatic cleavage
or by genetic engineering. For instance, a Fab fragment
is an antibody structure of about 50 kDa that still
binds to antigens but is monovalent with no Fc portion,
whereas Fab2 fragment antibodies have two antigen-
binding Fab portions linked together by disulphide bonds
and therefore are divalent with a molecular weight of
about 110 kDa. Fragments of the intact antibody may
exhibit shorter half-life, faster blood clearance and bet-
ter tumour penetration, resulting in faster and higher
signal-to-noise ratio. Furthermore, the removal of the
Fc segment could reduce the non-specific distribution
in vivo of the mAb via Fc receptors found on normalcells [13]. However, reduction in size can also reduce
antibody avidity [14], and the shortened serum half-life,
likely due to kidney clearance and lack of Fc-mediated
neonatal receptor recycling, may decrease the overall
tumour uptake of these small molecules [15].
Receptors on the surface of cells can serve as targets
for antibodies and antibody fragments, and if they are
expressed specifically by tumour cells, they are excellent
targets for radio-immunodiagnostics. There are several
promising receptors for radio-immunodiagnostics such
as EGFR and isoforms of CD44. CD44 belongs to a fam-
ily of glycoproteins serving as surface receptors for
extracellular matrix components, mainly hyaluronic acid.
The receptors are involved in migration and adhesion of
cells. Twenty exons encode CD44, and exons 6 to 15,
namely variable exons 1 to 10 (v1 to v10), can be alter-
natively spliced with diverse end products [16]. Most tis-
sues, both epithelial and non-epithelial, express variants
of CD44 with the exception of splice variants v4, v6 and
v9 which are more sparsely occurring [17]. For CD44v6,
the expression in normal tissue is restricted to squamous
and transitional epithelium [17,18]. The overexpression
of certain CD44 splice variants has been found to be in-
volved in cancer progression, and CD44v6 in particular
has been suggested to play a role in tumour formation,
invasion, and metastasis formation [16,19]. One pro-
posed mechanism for the increased metastatic potential
is binding to extracellular matrix components, enabling
invasion and angiogenesis [19,20]. Previous studies have
shown overexpression of CD44v6 in squamous cell car-
cinomas, for example, in the head and neck, lung, skin,
oesophagus, cervix and papillary thyroid cancers, and
several studies have demonstrated overexpression of
CD44v6 in over 90% of primary and metastatic HNSCC
[19,21]. This makes CD44v6 a promising candidate
marker for targeting of squamous cell carcinoma [22]. A
chimeric monoclonal antibody, cMAb U36, targeted at
CD44v6 has previously been evaluated both for diagnos-
tic and therapeutic uses with promising results [23-25],
as well as with a fully humanized version, BIWA-4, bind-
ing to an overlapping epitope in the v6 domain [26,27].
In a previous study, chimeric Fab and Fab2 fragments of
U36 radiolabelled with 125I were characterized in vitro
and in vivo and compared to the intact antibody.
Tumour-to-blood ratios and tumour penetration were
increased for Fab and Fab2 compared with the intact
antibody [12].
To date, few antibody fragments toward CD44v6 have
been reported, and none of them are fully human with a
thoroughly characterized binding site. Thus, to facilitate
improved targeting of CD44v6, we have selected in vitro
characterized fully human Fab fragments, derived from the
HuCAL PLATINUM library, which specifically recognize
v6-containing isoforms of CD44 [28]. Clones derived
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renewable source of human antibodies or antibody
fragments that can be expressed in Escherichia coli.
Furthermore, the recombinant origin of the antibody
fragments enables future reformatting to provide mol-
ecules that are optimized for either diagnostic or thera-
peutic applications [29]. One main candidate, AbD15179,
demonstrated optimal affinity and slow dissociation from
the tumour cells and was chosen for further evaluation.
To our knowledge, this study generated the first and most
thoroughly characterized fully human Fab fragment spe-
cific for CD44v6 [28].
The aim of this study was primarily to assess the
in vivo tumour targeting capabilities of the novel, fully
human, CD44v6-targeting antibody fragment AbD15179.
The Fab fragment was first evaluated for species specifi-
city using surface plasmon resonance (SPR) and was
then labelled with 111In or 125I, as models for radionu-
clides suitable for imaging with SPECT or PET. Specific
binding and internalization of labelled conjugates was
evaluated in CD44v6-expressing SCC cells in vitro, and
in vivo binding specificity and biodistribution studies
were then performed using 111In- or 125I-labelled Fab
fragments in a dual-isotope study in tumour-bearing
mice with xenografts of varying CD44v6 expression.
Methods
Antibody fragment AbD15179
The CD44v6-binding Fab fragment AbD15179 was sup-
plied from AbD Serotec (Kidlington, UK). It was selected
from an array of 13 different human antibody fragments,
all recognizing CD44v6. The selection and production of
this antibody fragment have been described previously
[28]. The native Fab fragment is referred to as AbD15179
throughout this paper. AbD15179 was supplied in 3× PBS
(0.72 μg/ml) and stored at −80°C. The fragment used
for 111In-labelling was separated by size-exclusion chro-
matography on a NAP-5 column (Amersham Biosciences,
Uppsala, Sweden) pre-equilibrated with purified (MilliQ,
Millipore Corp., Billerica, MA, USA) water. It was then
freeze-dried and stored at −20°C before use in order to fa-
cilitate buffer exchange and concentration adjustments.
Biosensor evaluation of species specificity of AbD15179
Two 16-mer peptides corresponding to the human
(CGNRWHEGYRQTPREDS) and mouse (CQNGWQG
KNPPTPSEDS) forms of the CD44v6 antigen used to
generate AbD15179 were produced by peptide synthe-
sis (Elim Biopharmaceuticals, Hayward, CA, USA). The
peptide antigens were individually conjugated to bovine
serum albumin (BSA) through N-terminal cysteine resi-
dues. Purified recombinant CD44v3-10 (see [28] for de-
tails) and the two carrier-conjugated peptides were
immobilized on a ProteOn XPR36 general layer mediumbiosensor chip (Bio-Rad, Hercules, CA, USA) using amine
coupling. This yielded immobilization levels of approxi-
mately 1,000 (CD44 isoform) and 300 (BSA-peptides) re-
sponse units, respectively. A CD44 isoform that lacks the
v6 region (CD44v3-10Δv6) was included as a negative
control in one channel. Dilution series of AbD15179
(0.6 to 50 nM) were injected at 25°C with a flow rate
of 50 μl/min. PBS containing 0.05% Tween 20 (pH 7.4)
was used as running buffer, and the surfaces were re-
generated using 10 mM HCl. The chimeric anti-
CD44v6 monoclonal antibody U36 [30] was used as a
positive control. Binding curves were normalized using
a blank ligand channel and a parallel buffer injection
prior to fitting to a 1:1 Langmuir isotherm using the
ProteOn manager software version 3.1.0.6 (Bio-Rad).
Cell lines
The human HNSCC cell line H314 (obtained from
European Collection of Cell Cultures, Salisbury, UK), de-
rived from floor of mouth, was cultured in a one-to-one
mixture of Ham's F12 and Dulbecco's modified eagle
medium (DMEM), supplemented with 10% foetal calf
serum, 2 mM L-glutamine, and antibiotics (100 IU peni-
cillin and 100 μg/ml streptomycin). H314 has demon-
strated an average antigen density of approximately
650,000 CD44v6 receptors [31]. The SCC cell line A431
(obtained from the American Type Culture Collection,
Manassas, VA, USA), derived from vulva, was cultured
in Ham's F10, with the same supplements. A431 has
been shown to be a highly CD44v6-expressing cell line
with approximately 3,000,000 receptors per cell [32]. As
a negative control, the breast cancer cell line MDA-MB-
231 (obtained from the American Type Culture Collec-
tion) was used. It was cultured in DMEM, with the same
supplements as above. This cell line has demonstrated
no detectable CD44v6 expression [31]. The cells were
incubated at 37°C in an atmosphere containing humidi-
fied air with 5% CO2. The cells used in the monolayer
culture experiments were trypsinized and seeded in sep-
arate dishes used for experiments 2 to 3 days prior to
the studies.
125I and 111In labelling of AbD15179
125I- and 111In-labelled AbD15179 have previously been
extensively evaluated in vitro [31]. In the present study,
AbD15179 was labelled with 125I (PerkinElmer, Waltham,
MA, USA) using direct chloramine T labelling [33]
(Sigma-Aldrich, St. Louis, MO, USA) as previously de-
scribed [28,31]. Generally, a stock solution of 10 MBq 125I
was mixed with 100 μl PBS, and 100 μg of the Fab frag-
ment (140 μl, 0.72 mg/ml in PBS) was added. The reaction
was initiated by the addition of chloramine T (Sigma-
Aldrich) in water (40 μl, 4 mg/ml) and was quenched
after a 5-min incubation on ice by the addition of
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NJ, USA) in water (80 μl, 4 mg/ml). Each labelled protein
was separated from non-reacted 125I and low-molecular-
weight reaction components on a NAP-5 column pre-
equilibrated with PBS. 125I-labelled AbD15179 is referred
to as 125I-Fab in this paper.
Labelling of AbD15179 with 111In (Mallinckrodt Medical
B.V., St. Louis, MO, USA) was done using CHX-A″-DTPA
labelling as described previously [31,34]. The chelator
CHX-A″-DTPA used for 111In labelling exhibits high affin-
ity for several isotopes that are suitable for either diagnostic
or therapeutic purposes, including 111In, 86Y, 90Y and 177Lu.
In short, to 75 μg AbD15179 solution (15 μl, 5 mg/ml in
borate buffer, pH 9), 4.1 μl of CHX-A″-DTPA solution
(1 mg/ml in borate buffer, 0.07 M, pH 9) was added, corre-
sponding to a chelator-to-AbD15179 molar ratio of 5:1.
The reaction mixture was incubated overnight at room
temperature, and the conjugated antibody was then sepa-
rated from free CHX-A″-DTPA using a NAP-5 column
equilibrated with acetate buffer (0.2 M, pH 5.5). Approxi-
mately 10 MBq of 111In in acetate buffer was then added to
the conjugated AbD15179, and the reaction mixture was
allowed to incubate for 30 min at room temperature. La-
belled Fab fragment was then separated from the non-
reacted radionuclide and low-molecular-weight reaction
components by using a NAP-5 column pre-equilibrated
with PBS. 111In-labelled AbD15179 is referred to as 111In-
Fab in this paper.
To determine the purity and stability of the labelled
antibody fragments, instant thin-layer chromatography
(ITLC) was performed on 125I- and 111In-labelled conju-
gates. The purity of the samples taken immediately, as
well as stored at 4°C for 48 h, was analysed. Approxi-
mately 1 μl of the conjugate was placed on a chromatog-
raphy strip (Biodex, Shirley, NY, USA) and placed into a
‘running buffer’ (70% acetone or 0.2 M citric acid for
125I and 111In, respectively), followed by measurements
on a Cyclone Storage Phosphor System (PerkinElmer).
The data were analysed using the OptiQuant image ana-
lysis software (PerkinElmer). Furthermore, stability in
murine serum was evaluated using sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
analysis (200 V constant) on NuPAGE® 4-12% Bis-Tris
gel (Novex, Thermo Fisher Scientific, Waltham, MA,
USA). Briefly, 1.8 μg of 125I-Fab or 111In-Fab was incu-
bated in 120 μl of murine serum (42% in PBS, pH 7.4)
for 60 min at 37°C. After incubation, the samples were
treated with NuPAGE® LDS Sample Buffer according to
the manufacturer's instructions and loaded on the gel.
One well was loaded with 4 μl of HiMark™ Pre-Stained
Protein Standard (Novex®). Measurements were per-
formed on a Cyclone Storage Phosphor System, and the
data were analysed using the OptiQuant image analysis
software.In vitro binding, specificity and internalization
In vitro binding and specificity were assessed for 125I-Fab,
and binding, specificity and internalization were assessed
for 111In-Fab using both H314 and A431 cells. For binding
and specificity measurements, 10 nM 125I-Fab or 111In-
Fab was added to each dish and incubated for 2 to 24 h.
To some of the dishes, a 100-time molar excess of un-
labelled antibody fragment was simultaneously added for
assessment of binding specificity. After incubation, the
cells were washed with serum-free medium to remove un-
bound antibody fragment, detached with 0.5 ml trypsin at
37°C and resuspended in 1 ml complete medium. A sam-
ple of 0.5 ml of the cell solution was taken for cell count-
ing, and the remaining 1 ml was collected for radioactivity
measurements.
For internalization measurements, 10 nM 111In-Fab
was added to each dish and incubated for 2 to 24 h
using the following conditions: (i) incubation at 37°C to
allow internalization of the conjugate, (ii) incubation at
37°C in the presence of a 100-time molar excess of un-
labelled antibody for assessment of binding specificity
and (iii) incubation at 0°C for correction of acid-
resistant surface binding at non-internalizing conditions.
After incubation, the cells were washed with serum-free
medium to remove unbound antibody and incubated at
0°C with 20 mM HCl/150 mM NaCl (pH 1.7) for
15 min to release antibodies bound to the cell surface.
The supernatant was collected, and the radioactivity was
counted in a gamma counter to assess the amount of
membrane-bound conjugates. Finally, the cells were lysed
with 0.1 M NaOH/1% Triton X-100, and the radioactivity
was measured in a gamma counter to assess the amount
of internalized conjugates. After correction for acid-
resistant surface binding, the internalization at 37°C was
calculated as the percentage of the total amount of radio-
activity specifically bound (internalized and surface-
bound) to the cells.
In vivo specificity
Tumour xenografts were formed by subcutaneous inocu-
lation of approximately 8 × 106 A431 cells (high CD44v6
expression) suspended in 300 μl injected medium in the
right posterior leg, and approximately 8 × 106 MDA-MB-
231 cells (no CD44v6 expression) in the left posterior leg,
in five nude balb/c (nu/nu) female mice. The mice were
housed in a controlled environment and fed ad libitum.
All experiments complied with the current Swedish law
and were performed with permission granted by the Upp-
sala Committee of Animal Research Ethics.
After allowing the tumours to grow for 2 weeks, the ani-
mals were injected with125I-Fab (5 μg in 200 μl PBS,
100 kBq, rendering a specific activity of 20 kBq/μg) in the
tail vein. After 24 h, the animals were euthanized with a
mixture of ketamine and xylazine followed by heart
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were excised and weighed. Radioactivity content of the
blood and tumours was measured in a gamma counter, to-
gether with three injection standards of 200 μl 125I-Fab
(volume of injection). A mean injected dose was calcu-
lated from the injection standards, and the injected activity
of 125I-Fab for each mouse was calculated by subtracting
the residual activity in the syringe from the mean injected
dose. Radioactivity uptake in the organ was calculated as
percent of injected activity per gram of tissue (%ID/g).
Tumour-to-organ ratio was calculated as activity/gtumour
divided by activity/gorgan.
Biodistribution
Tumour xenografts of A431 and H314 cells (high and
moderate CD44v6 expression, respectively) were formed
in 20 nude balb/c (nu/nu) female mice as described
above. The mice were housed in a controlled environ-
ment and fed ad libitum. The experiments complied
with the current Swedish law and were performed with
permission granted by the Uppsala Committee of Ani-
mal Research Ethics.
Three weeks after tumour cell injection, the animals re-
ceived an intravenous injection via the tail vein with125I-
Fab (100 kBq, specific activity of 20 kBq/μg) and 111In-Fab
(100 kBq, specific activity of 20 kBq/μg), totally 5 μg Fab
fragments in 200 μl PBS. At 6 h (N = 5), 24 h (N = 5), 48 h
(N = 5) and 72 h (N = 5) post injection, the animals were
euthanized with a mixture of ketamine and xylazine
followed by heart puncture, and blood was aspirated and
weighed. The tumours, salivary glands, thyroid (en bloc
with larynx), tongue, liver, kidneys, spleen, urinary bladder,
colon, upper gastrointestinal tract, skin, bone and muscle
were excised and weighed, and radioactivity was measured
in a gamma counter. The tail and the rest of the body
were also separated, weighed and measured in a gamma
counter, together with three injection standards for each
group. The injected dose was calculated as described
above. Radioactivity uptake in the organ was calculated as
%ID/g. Uptake was calculated as percent of injected activ-
ity per organ. Tumour-to-organ ratio was calculated as ac-
tivity/gtumour divided by activity/gorgan.
Statistical analyses
Statistical analyses were performed using GraphPad Prism
Version 5.02 for Windows (GraphPad Software, Tumour
Biol Inc., La Jolla, CA, USA, http://www.graphpad.com).
For in vivo specificity studies, the differences in 125I-Fab
uptake between MDA-MB-231 tumours and A431 tu-
mours were assessed using a two-tailed paired t test and
were considered statistically significant if P < 0.05. In the
biodistribution studies, the data are presented as the
mean ± standard deviation (SD). The significance of differ-
ences between the groups over time was tested with one-way analysis of variance (ANOVA) with Newman-Keuls
multiple comparison test. The differences were considered
statistically significant if P < 0.05. The differences in 125I-
Fab or 111In-Fab uptake between H314 tumours and A431
tumours were assessed using repeated measures ANOVA
with Newman-Keuls multiple comparison test and were
considered statistically significant if P < 0.05.
Results
Biosensor evaluation of species specificity of AbD15179
The Fab fragment AbD15179 bound strongly to the hu-
man v6 peptide, whereas no binding was detected for
the murine form of the target (Figure 1). The same bind-
ing pattern was observed for U36 as expected. The low
nanomolar target binding affinity (KD < 7 nM) of AbD15179
reported previously [28] was verified using triplicate injec-
tions and two different immobilization levels of CD44v6-10.
As observed earlier, the affinity for the conjugated peptide
target was roughly tenfold lower than that for the full-length
extracellular domain CD44v3-10, which was a result of
both a faster dissociation rate constant and a slower
association.
Labelling
Labelling yields for 125I and 111In labelling of AbD15179
for in vitro studies were 50% and 39%, rendering specific
activities of 50 and 52 kBq/μg, respectively. The labelling
yield for 125I labelling of AbD15179 for in vivo specificity
studies was 66%, and for biodistribution studies 74%,
rendering specific activities of 66 and 74 kBq/μg, re-
spectively. Specific activities were adjusted to 20 kBq/μg
for all in vivo conjugates, using unlabelled AbD15179,
before injections. The purity of the labelled proteins
was >99.9% according to the ITLC analysis. The label-
ling yield for 111In labelling of AbD15179 for biodistri-
bution studies was 63%, resulting in a specific activity
of 84 kBq/μg, and the purity of the labelled protein
was >96% according to the ITLC analysis. The purity
of labelled conjugates stored in PBS at 4°C was re-
analysed 48 h post injection (p.i.) and was unchanged
according to the ITLC analysis. SDS-PAGE analysis of
the sample incubated in serum for 1 h at 37°C showed
a single radioactivity peak corresponding to the size of the
intact Fab fragment for both 125I-Fab and 111In-Fab, indi-
cating high stability of the fragments.
In vitro binding, specificity and internalization
Cellular binding of 111In-Fab and 125In-Fab increased with
time, levelling out at approximately 6 h in both cell lines.
Furthermore, binding of 111In-Fab and 125In-Fab was
blocked by an excess of unlabelled AbD15179 in both cell
lines, demonstrating specific binding of the conjugates
(Figure 2). Internalization studies of 111In-Fab demon-







































Figure 1 SPR evaluation of the Fab fragment AbD15179 to (A) human and (B) mouse CD44v6 peptides. AbD15179 clearly bound to the
human CD44v6 peptide, whereas no signal was detected for mouse CD44v6.
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AbD15179 have previously been extensively evaluated
in vitro [31]. In brief, both 125I-Fab and 111In-Fab bound
specifically to CD44v6-expressing cells and demonstrated
a general biphasic appearance of one high- and one low-
affinity binding event. The population of high-affinity
binders was significantly higher for 111In-Fab than that
for 125I-Fab, which resulted in longer retention of
111In-Fab compared to 125I-Fab on SCC cells. The equi-
librium dissociation constant (KD) for the high-affinity
population (measured using cell-based real-time measure-
ments and interaction analysis) was approximately 8 ± 2
nM and did not significantly differ between 125I- or 111In-
labelled AbD15179 on the H314 or A431 cells [31].
In vivo specificity
The specificity of AbD15179 was assessed in vivo by
comparing the uptake of 125I-Fab in CD44v6-negative
(MDA-MB-231) and CD44v6-positive (A431) tumours
24 h p.i. in tumour-bearing mice. At the time of the ex-
periments, median tumour weight for MDA-MB-231 tu-
mours was 131 mg, generally ranging between 90 mg
(lower quartile) and 338 mg (upper quartile). For the
A431 tumours, the median weight was 62 mg, generally
ranging between 43 and 95 mg. There was no correl-
ation between the tumour weight and %ID/g of 125I-Fab.
Tumour uptake differed significantly between the CD44v6-
negative and CD44v6-positive tumours, with the CD44v6-positive A431 tumours displaying more than two times
higher uptake than the CD44v6-negative MDA-MB-231
tumours (0.66 ± 0.13 (%ID/g ± SD) and 1.34 ± 0.26 %ID/g
for MDA-MB-231 and A431 tumours, respectively).
Biodistribution
The biodistribution of AbD15179 was assessed in vivo
by comparing the uptake of 125I-Fab and 111In-Fab in
mice bearing both CD44v6-moderate (H314) and CD44v6-
positive (A431) tumours. At the time of the experiments,
the median tumour weight for the H314 tumours was
23 mg, generally ranging between 17 mg (lower quartile)
and 33 mg (upper quartile), and the median tumour weight
for the A431 tumours was 105 mg, generally ranging
between 86 and 294 mg. There was no correlation be-
tween tumour weight and %ID/g of 125I-Fab or 111In-
Fab. The biodistribution data of the selected organs of
the 125I-Fab and 111In-Fab fragments in tumour-bearing
mice are shown in Figure 3. The selected organs were the
ones in the vicinity of the head and neck region, tongue,
salivary glands and thyroid, as well as the organs of high
interest for radio-immunotargeting such as liver, kidneys
and spleen. Generally, 111In-Fab displayed not only higher
uptake of radioactivity and slower clearance in most
organs compared with 125I-Fab but also a higher tumour-
to-blood ratio and a clearer discrimination between
high- and moderate-CD44v6-expressing tumours. The
biodistribution data are described in more detail below.
Figure 2 Cellular uptake (A) and specificity (B) of 111In-Fab and
125I-Fab in cultured cells. (A) Cellular uptake of 111In-Fab (straight
line) and 125I-Fab (broken line) during incubation for 0 to 24 h in H314
cells. Error bars represent SD (N= 3 to 6). (B) Specificity of 111In-Fab and
125I-Fab in H314 and A431 cells. Grey bars show uptake in unblocked
cells, whereas black bars show uptake in cells blocked with an excess of
unlabelled AbD15179. Error bars represent SD (N= 3 to 8).
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tively stable over time in both the moderate (H314) and
high (A431) CD44v6-expressing tumour models, with
no significant changes in tumour uptake over time
(Figure 3A). 111In-Fab displayed a clear difference in
tumour uptake between the moderate- and high-CD44v6-
expressing tumours, ranging between 1.5 to 2 times higher
for the high-CD44v6-expressing A431 tumours (calculated
for each individual mouse) throughout the study. At 6 h p.i.,
the percentage of the injected dose per gram of 111In-Fab in
the moderate-CD44v6-expressing H314 tumours was 2.4 ±
1.1 (SD) and remained at this level. The uptake in the high-
CD44v6-expressing A431 tumours was significantly higher,
being 4.6 ± 1.9 %ID/g at 6 h p.i., with a slight, although not
significant, decrease over time to 3.2 ± 0.2 %ID/g at 72 h p.i.
For blood, bone and organs, 111In-Fab demonstrated highest
activities at the first time point (6 h), declining with time.
The kidneys displayed the highest activity (131 ± 47 %ID/gat 6 h), which rapidly decreased to 67 ± 11 %ID/g by 24 h.
The second highest normal organ uptake was observed in
the liver (13 ± 5.6 %ID/g at 6 h), rapidly decreasing to 5.6 ±
1.4 %ID/g by 24 h.
125I-Fab generally displayed lower uptake values
than 111In-Fab in both tumours and normal organs,
with a more pronounced clearance and decrease in activ-
ity over time (Figure 3B). At 6, 24, and 48 h p.i., 125I-Fab
displayed a difference in tumour uptake between the high-
and moderate-CD44v6-expressing tumours, although not
as pronounced as for 111In-Fab, ranging between 1.3 and
1.4 times higher for the high-CD44v6-expressing A431 tu-
mours compared to the medium-CD44v6-expressing
H314 tumours. At 72 h p.i., there was no difference in ac-
tivity between the tumours. A clear decrease in tumour
activity was seen from 6 to 24 h p.i. in both tumour
models. In high-CD44v6-expressing A431 tumours, this
decrease was also significant between 48 and 72 h p.i. At
6 h p.i., the activity of 125I-Fab in the moderate-CD44v6-
expressing tumours was 1.1 ± 0.6 %ID/g, steadily decreas-
ing over time, reaching 0.25 ± 0.07 %ID/g at 72 h p.i. In
the high-CD44v6-expressing A431 tumours, the activ-
ity of 125I-Fab was 1.6 ± 0.1 %ID/g at 6 h, decreasing to
0.22 ± 0.03 %ID/g at 72 h p.i. As for the 111In conju-
gate, the organ with the highest activity was the kidney
(6.5 ± 2.1 %ID/g at 6 h), with the activity rapidly de-
creasing to 1.4 ± 0.2 at 24 h. The stomach and salivary
glands displayed high initial values, both rapidly de-
creasing to below 0.3 %ID/g 48 h p.i. The exception to
this trend was uptake in the thyroid, where no de-
crease in activity was observed (Figure 3B, inset).
In order to assess the selectivity of tumour targeting for
the 111In-Fab and 125I-Fab conjugates, tumour-to-normal
tissue ratios were calculated based on the high-CD44v6-
expressing A431 tumours (Figure 4), and tumour-to-
blood ratios were calculated for both tumour types
(Figure 4, insets). The tumour-to-organ ratios for 111In-Fab
increased over time for most organs of interest including
the blood (Figure 4A) and were highest at 48 and 72 h p.i.
The tumour-to-blood ratios for both A431 and H314 tu-
mours increased over time with a ratio of over 10 for A431
tumours at 72 h p.i. (Figure 3A, inset). Also, for 125I-Fab,
the tumour-to-organ ratios increased over time (Figure 3B).
The tumour-to-blood ratios increased with time for both
tumours with a maximum ratio at 72 h above 4 in both
A431 and H314 tumours (Figure 3B, inset). In the spleen,
liver and kidney, higher tumour-to-normal tissue ratios
generally were observed with 125I-Fab, while the opposite
behaviour was seen in the blood, tongue and salivary
glands, where 111In-Fab displayed higher ratios.
Discussion
Detecting small metastases and small primary tumours
in patients with HNSCC could improve staging and















































































































































A 111In-Fab B 125I-Fab
Figure 3 Biodistribution of (A) 111In-Fab and (B) 125I-Fab in tumours and organs of SCC tumour-bearing mice. The target antigen CD44v6
is expressed moderately in H314 tumours and to a high extent in A431 tumours. The animals were sacrificed at 6-h (black bars), 24-h (dark grey),
48-h (light grey) and 72-h (white) post injection. The data are expressed as percentages of injected activity per gram of tissue, %ID/g, except for
the thyroid (inset), which is expressed as percentages of injected activity per organ. Error bars represent SD (N = 5)
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stage correlates closely to survival, and if treatment can be
individualized through better staging, survival rates should
improve. Although there are several diagnostic methods
available today, major difficulties in finding small tumours
and detecting minimal residual disease still remain. A spe-
cific targeting molecule labelled with an appropriate radio-
nuclide utilized in a SPECT or PET setting could add
considerably to existing methods. This kind of molecular
imaging offers the ability to visualize, characterize and
measure processes on molecular and cellular levels non-
invasively in living systems. Additionally, fused imaging
modalities such as PET/CT, PET/MRI and SPECT/CT
have enabled the combination of anatomy and molecular
events into a single image [9]. The antibody fragment
AbD15179 recognizes the CD44v6 antigen, which has
shown consistent expression in many primary squamous
cell carcinomas but only in a subset of normal tissues
[17]. The potential of CD44v6 as a target for radio-
immunotargeting agent has been demonstrated in previ-
ous studies using full-length antibodies [23,24]. However,
very few antibody fragments toward this target have been
reported, and none of them are fully human with a thor-
oughly characterized binding site. This study represents,to our knowledge, the first in vivo evaluation of a fully hu-
man CD44v6-targeting antibody fragment.
The objective of this study was to evaluate, for the first
time, the in vivo properties of the CD44v6-targeting frag-
ment AbD15179, labelled with 111In or 125I, and to assess
its utility as a targeting agent for radio-immunodiagnostics
of CD44v6-expressing tumours. Species specificity, antigen
specificity and internalization properties were first assessed
in vitro. In vivo specificity and biodistribution was then
evaluated in tumour-bearing mice, using a dual-tumour
and dual-isotope setup. An advantage of using this setup is
the possibility to evaluate uptake in a low/moderate-
CD44v6-expressing tumour vs. a high-CD44v6-expressing
tumour, normalizing each dataset to the same mouse. This
can minimize the effects of potential differences among
groups of experimental animals such as tumour size
and injection variability. In the same way, the effects of 111In
vs. 125I labelling of the fragment can be evaluated.
In vitro, both species-specific and antigen-specific bind-
ing of the conjugates were demonstrated, with no detect-
able internalization. The lack of binding of AbD15179 to
the murine v6 peptide was expected, since 9 of the 16 resi-
dues in the peptides differ between the murine and human
variants [35]. Furthermore, the two consecutive proline
Figure 4 Tumour-to-organ ratios of (A) 111In-Fab and (B) 125I-Fab in tumours and organs of SCC tumour-bearing mice. A431 tumours
were used as reference for tumour-to-organ ratio calculations. The animals were sacrificed at 6 h (black bars), 24 h (dark grey), 48 h (light grey)
and 72 h (white) post injection. Inset: tumour-to-blood ratios of radiolabelled Fab for both A431 and H314 tumours. Error bars represent SD (N = 5).
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may distort the conformation of murine CD44v6 in the
targeted region. The low internalization was also in line
with previous studies of CD44v6, which have shown that
CD44v6 is commonly not an internalizing receptor
[32,36]. Generally, high tumour internalization of a radio-
conjugate is considered beneficial for radiometals such as
111In, since internalization of a residualizing radiometal
will cause long tumour retention times, often outweighing
disadvantages of radiometals such as accumulation in the
liver, spleen and kidneys [37]. Thus, the lack of internal-
ization shown in vitro could favour a radiohalogen before
a radiometal as a radiolabel in vivo for AbD15179. How-
ever, in a previous in vitro study of this fragment, we could
demonstrate that the binding characteristics of 111In-Fab
were more favourable than those for 125I-Fab, even in a
non-internalizing setting, resulting in longer retention
of 111In-Fab compared to that of 125I-Fab on SCC cells
[31]. Thus, we considered 111In-Fab to be an interest-
ing candidate for the subsequent in vivo studies, des-
pite an expected low internalization rate.
In vivo, we first demonstrated a CD44v6-dependent
tumour uptake for AbD15179, with a markedly higher
tumour uptake of 125I-Fab in high-CD44v6-expressing
tumours compared to the CD44v6-negative tumours, es-
tablishing the specificity of the conjugate also in vivo.
Tumour uptake (%ID/g) differed significantly between the
CD44v6-negative and CD44v6-positive tumours, with theCD44v6-positive A431 tumours displaying more than two
times higher uptake than the CD44v6-negative MDA-MB-
231 tumours. This is in line with the values obtained at
the same time point (24 h p.i.) in the subsequent bio-
distribution study in this paper, in which high-CD4
4v6-expressing A431 tumour uptake of 125I-Fab was
approximately 1.3 times higher than the uptake in the
moderate-CD44v6-expressing H314 tumours. However, at
later time points, the difference in tumour uptake between
moderate- and high-CD44v6-expressing tumours was di-
minished for 125I-Fab, whereas 111In-Fab displayed a clear
difference in tumour uptake between the moderate- and
high-CD44v6-expressing tumours, ranging between 1.5 to
2 times higher for the high-CD44v6-expressing tumours
throughout the study. Thus, we conclude that 111In-Fab
displayed higher in vivo target sensitivity at the adminis-
tered dose.
111In-Fab also demonstrated a higher tumour uptake
than 125I-Fab at all time points, being more than 15
times higher at the last time point (72 h p.i.). The accu-
mulation and slower dissociation of 111In-Fab in tu-
mours were in line with the slower off-rate of 111In-Fab
compared to 125I-Fab observed on these tumour cells
in vitro shown in a preceding study [31] using non-
internalizing conditions, as discussed previously. However,
the effect seen in vivo could nevertheless in part be due to
some internalization of the 111In-Fab by the tumour cells
as the cellular membrane renews itself, even though
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tion of 111In-Fab into either H314 or A431 tumour cells
up to 24 h of incubation at 37°C.
For successful imaging, the contrast between tumour
and surrounding tissue is of even higher importance
than the total tumour uptake. In the present study,
tumour-to-blood ratios were above 1 already at 24 h p.i.
for both conjugates and continued to increase through-
out the study. This can be compared to previous studies,
where successful CD44v6 imaging in tumour-bearing
mice using both 111In [38] and 124I [39] coupled to a
CD44v6-targeting antibody was performed, despite three
to four times lower tumour-to-blood ratios at the time
of imaging than in our current study. We believe that
this is very promising and demonstrates that imaging
with 111In- or 124I-labelled AbD15179 is indeed feasible.
In general, 125I-labelled Fab fragments were cleared
from the circulation more rapidly than the 111In-Fab
fragments. This is in line with several other studies
using 125I- and 111In-labelled molecules, in which the 125I-
labelled compounds have generally shown lower uptake
and faster clearance from organs. The reason for this has
been suggested to be dehalogenation of the radioiodinated
protein or exchange of 111In into iron-binding proteins
[37]. Another explanation for the more rapid clearance
could be a higher amount of aggregation of 125I-Fab than
for 111In-Fab [31], resulting in an increase in the effective
size and, thus, clearance from the circulation via a size-
dependent mechanism, as has been shown previously for
liposomes [40].
Furthermore, 111In-Fab displayed a considerably higher
uptake than 125I-Fab in the liver, spleen and kidneys.
These observations are also in agreement with those re-
ported in the literature when 125I and 111In are com-
pared [37]. The observed increase of 111In in the liver
could be a result of antibody clearance or exchange with
iron-binding protein or a mixture of both processes. The
accumulation of 111In in the kidneys can probably be at-
tributed to the active filtration of the fragments and
probably to the subsequent exchange of 111In into non-
binding proteins within this organ [41]. The property of
the liver and kidneys to accumulate 111In and clear it
more slowly is a distinct disadvantage of 111In and may
limit its use, although this should be balanced by the fact
that for 111In-Fab, the magnitude of tumour uptake was
several times higher than seen with the radioiodinated
fragment. Additionally, several preclinical and clinical
experiments have shown that undesirable renal uptake
of 111In can be reduced with pretreatment with e.g. cat-
ionic amino acids such as lysine [42-44]. Moreover, with
the aim to discriminate between tumour/metastases and
surrounding tissue in the head and neck cancer region,
renal uptake is of less concern for imaging of head and
neck cancer, although it may limit the amount of activitythat can be administered to patients due to dose-limiting
toxicity to the kidneys.
For imaging in head and neck cancer, tumour-to-tissue
contrast of muscle, salivary glands, thyroid and, to some
extent, bone is important, in addition to the tumour-to-
blood ratio. Some normal mouse tissues containing
squamous and transitional epithelium, such as tongue
and skin, express murine CD44v6. However, we demon-
strate in this study that AbD15179 does not cross-react
with the murine CD44v6. Thus, studies with fragments
cross-reactive with murine CD44v6 would be needed to
study the effect of CD44v6 expression in normal tissues
in a mouse model. Consequently, assuming that only
non-CD44v6-mediated uptake was measured, our data
indicate that there was no unspecific accumulation of
125I-Fab or 111In-Fab in any normal tissue. The transfer-
ability of the results to targeting HNSCC in humans is
still somewhat limited, at least for organs with known
CD44v6 expression as the epithelia of the oral cavity
[17,18]. However, previous clinical studies of CD44v6-
binding antibodies have been performed for several
CD44v6-tageting antibody conjugates for both radio-
immunotherapy and radio-immunodiagnostics
[23,26,45,46], demonstrating no selective accumulation
at non-tumour sites, except in faeces and urine [25], and
only minimal accumulation of activity in mouth, lung,
spleen, kidney, bone marrow and scrotal area [27]. Since
we have previously shown that AbD15179 at least partly
binds to the same epitope as these antibodies [28], this
is promising for the future clinical applicability of our
fragment.
The isotopes that have physical and nuclear properties
suitable for in vivo imaging use are relatively limited. In this
study, we used 111In as a model for radiometals, and 125I as
a model for radiohalogens. The choice of radionuclide and
the labelling method is an important aspect in successful
radio-immunotargeting, and additional improvements in
tumour-to-blood ratio could probably be achieved by
further optimizing or changing labelling methods or
radionuclides. For 111In labelling, a CHX-A″-DTPA
chelator-to-Fab molar ratio of 5:1 was chosen. It is
possible that a different molar ratio could influence
targeting properties of the conjugate. However, in a
previous study, conjugation of 111In was studied at
three different molar ratios (5:1, 10:1 and 20:1) of
CHX-A″-DTPA chelate to panitumumab Fab2 in vitro
and in vivo. The different ratios had minimal effect on
the immunoreactivity and specific binding [11]. For
radioiodination, direct CAT labelling was used, as it is
a fast and simple method with high immunoreactive
fraction yield, rendering high specific activity. 125I was
used as a surrogate for radionuclides more suitable for
imaging such as 124I, or 131I for therapy. The thyroid
uptake was relatively high for 125I-Fab, most likely due
Haylock et al. EJNMMI Research 2014, 4:11 Page 11 of 13
http://www.ejnmmires.com/content/4/1/11to uptake of the free lipophilic iodine catabolites after
proteolytic degradation of the antibody fragment. Like-
wise, the initially high uptake in salivary glands and
stomach indicates iodine catabolites, since the Na+/I−
symporter mediates active I− transport also in these
tissues [47]. Values in the same order have previously
been reported for directly labelled 125I antibody conju-
gates [39,48]. By using other labelling strategies or by
blocking thyroid uptake using, e.g. potassium iodide,
thyroid uptake may possibly be reduced [48].
Although intact monoclonal antibodies have been con-
sidered candidates for radio-immunodiagnostics due to
their specificity, the long residence time in the blood, of
days to weeks, limits their applicability. Several studies
have demonstrated that the size of antibody-based im-
aging agents is inversely related to their blood clearance
[9]. Consequently, normal tissue exposure will be greater
with the intact antibody than for the fragment, impairing
tumour contrast. Fab fragments, approximately 50 kDa
in size, have been developed predominantly as imaging
agents. A possible disadvantage of Fab fragments is that
their molecular weight subjects them to glomerular fil-
tration. High uptake of antibody fragments in the kid-
neys has been reported before [49,50], most likely a
result of reabsorption by the renal tubular cells and ca-
tabolism [51]. It is possible that with a larger format,
such as Fab2 with a size above the renal threshold [52],
the fragments would exhibit a biodistribution shift from
the kidneys to the liver and may also improve affinity
and tumour uptake even further. This will be assessed in
a future study.
Another limitation of Fab fragments pertains to the fact
that they are monovalent, often resulting in the loss of
functional affinity and reduced binding strength compared
to e.g. Fab2 or IgG. However, in vitro evaluations of our Fab
fragment using SPR demonstrated KD in the low nanomo-
lar range, which is considered optimal for imaging [53].
Studies with 125I-labelled Fab fragments with lower affinity
(KD 30 ± 8 nM) derived from the CD44v6-targeting
chimeric antibody U36 [13] have previously been per-
formed in our group. The 125I-U36-Fab fragments demon-
strated lower tumour uptake and lower tumour-to-blood
ratios compared to the 125I-Fab in the present study, as well
as less optimal tumour-to-organ ratios for e.g. salivary
glands, tongue, thyroid and bone. The differences may be
the result of many different aspects, for example, tumour
cell line and size, as well as administered dose and specific
activity of the conjugates. However, since AbD15179 was
selected from a large number of fragments due to its high
affinity and very slow dissociation from tumour cells [28],
one hypothesis for the superior targeting qualities of
125I-Fab compared to those of 125I-U36-Fab may be the
desirable kinetic properties of 125I-Fab. Thus, we be-
lieve that not only the fully human format but also thesuitable affinity of AbD15179 will be an advantage for
radio-immunodiagnostics.
Conclusion
We have, for the first time, evaluated the in vivo proper-
ties of the AbD15179 Fab fragment targeted against
CD44v6 labelled with 111In or 125I and assessed its utility
as a targeting agent for radio-immunotargeting of HNSCC.
Our study demonstrated that 111In-Fab displayed a super-
ior tumour-to-blood ratio in high-expressing CD44v6
tumours at all time points compared to 125I-Fab. Fur-
thermore 111In-Fab was able to discriminate between
moderate and high CD44v6 expression in vivo. We
conclude that AbD15179 efficiently targets CD44v6-
expressing squamous cell carcinoma xenografts, and
particularly, the 111In-Fab displayed high and specific
tumour uptake. CD44v6 emerges as a suitable target
for radio-immunodiagnostics, and a fully human anti-
body fragment such as AbD15179 can enable further
clinical imaging studies.
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